AstraZeneca (AZN -1.6%) is partnering with Ironwood Pharmaceuticals (IRWD -1.6%) to co-develop...

AstraZeneca (AZN -1.6%) is partnering with Ironwood Pharmaceuticals (IRWD -1.6%) to co-develop and co-commercialize IRWD's linaclotide in China. Linaclotide is the first and only guanylate cyclase-C agonist approved by the FDA. Under the terms of the agreement, AZN will make an upfront payment of $25M to IRWD and will share in the net profits and losses. IRWD will also be eligible for $125M in additional sales-related milestone payments.

From other sites
Comments (1)
  • norjud
    , contributor
    Comments (468) | Send Message
    What is this drug use to treat?
    23 Oct 2012, 05:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs